Henry Schein (NASDAQ:HSIC) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Henry Schein (NASDAQ:HSIC) from a hold rating to a buy rating in a research note published on Monday.

HSIC has been the subject of several other reports. BMO Capital Markets assumed coverage on shares of Henry Schein in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 price objective for the company. Robert W. Baird set a $97.00 price target on Henry Schein in a report on Wednesday, May 6th. Stifel Nicolaus set a $95.00 price objective on Henry Schein in a research note on Wednesday, August 5th. Mizuho decreased their target price on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Finally, Barrington Research set a $104.00 price target on Henry Schein in a research report on Wednesday, August 5th. Eight equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Henry Schein presently has an average rating of “Hold” and an average target price of $92.27.

Henry Schein Stock Performance

HSIC stock opened at $89.52 on Monday. The company has a quick ratio of 0.73, a current ratio of 1.32 and a debt-to-equity ratio of 0.60. The business’s fifty day simple moving average is $85.04 and its two-hundred day simple moving average is $79.16. Henry Schein has a twelve month low of $61.94 and a twelve month high of $92.18. The firm has a market cap of $9.98 billion, a price-to-earnings ratio of 26.10, a PEG ratio of 1.71 and a beta of 0.80.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.03. The business had revenue of $3.46 billion during the quarter, compared to the consensus estimate of $3.37 billion. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period last year, the company earned $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Analysts predict that Henry Schein will post 5.35 earnings per share for the current year.

Hedge Funds Weigh In On Henry Schein

A number of large investors have recently added to or reduced their stakes in the company. CYBER HORNET ETFs LLC purchased a new position in shares of Henry Schein in the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc bought a new position in shares of Henry Schein during the 2nd quarter worth approximately $27,000. Federated Hermes Inc. purchased a new stake in Henry Schein during the fourth quarter valued at approximately $32,000. Los Angeles Capital Management LLC purchased a new stake in Henry Schein during the fourth quarter valued at approximately $37,000. Finally, Trust Co. of Vermont acquired a new stake in Henry Schein in the second quarter valued at approximately $42,000. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.